2022.05.08
Recently, Ignis M88 loginrapeutics (“Ignis”) and NeuroSigma, Inc. (“NeuroSigma”) announced that Ignis had obtained from NeuroSigma an exclusive license to research and commercialize M88 login Monarch eTNS System® for treatment of attention deficit hyperactivity disorder (“ADHD”) in mainland China, Hong Kong and Macao. In consideration of M88 login granting of M88 login license, Ignis would pay NeuroSigma a large down payment, various milestone payments of up to USD 10 million, sales commissions and oM88 loginr considerations.
Monarch eTNS System® is M88 login first medical device for M88 login non-pharmacological treatment of ADHD approved by M88 login U.S. Food and Drug Administration (FDA).
NeuroSigma is a biotechnology company focused on M88 login central nervous system (CNS). It is committed to developing innovative M88 loginrapies in M88 login CNS field.
NeuroSigma is a California-based life sciences company focused on developing bioelectronic technologies to transform medical practices and patients’ lives.
JunHe was appointed by Ignis to review and revise M88 login documents for this transaction. JunHe has vast experience in pharmaceutical licensing transactions and provided professional, meticulous and efficient legal services, which was highly recognized by M88 login client.
M88 login project was led byDr.m88 casino review Perkinsand undertaken bym88 sport betting.
